Pharmacological Intervention in Children with Autism Spectrum Disorder with Standard Supportive Therapies Significantly Improves Core Signs and Symptoms: A Single-Center, Retrospective Case Series

Hamza A Alsayouf,1 Haitham Talo,1 Marisa L Biddappa,1 Mohammad Qasaymeh,2 Shadi Qasem,3 Emily De Los Reyes4 1Kids Neuro Clinic and Rehab Center, Dubai, United Arab Emirates; 2Pediatric Neurology, Dent Neurological Institute, Amherst, NY, USA; 3Pathology and Laboratory Medicine, University of Kentuck...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Alsayouf HA, Talo H, Biddappa ML, Qasaymeh M, Qasem S, De Los Reyes E
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	risperidone aripiprazole antipsychotic comorbid challenging behaviors. Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/b1791cdb32f448f2993bad759a6eb043
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b1791cdb32f448f2993bad759a6eb043
record_format	dspace
spelling	oai:doaj.org-article:b1791cdb32f448f2993bad759a6eb0432021-12-02T11:06:02ZPharmacological Intervention in Children with Autism Spectrum Disorder with Standard Supportive Therapies Significantly Improves Core Signs and Symptoms: A Single-Center, Retrospective Case Series1178-2021https://doaj.org/article/b1791cdb32f448f2993bad759a6eb0432020-11-01T00:00:00Zhttps://www.dovepress.com/pharmacological-intervention-in-children-with-autism-spectrum-disorder-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Hamza A Alsayouf,1 Haitham Talo,1 Marisa L Biddappa,1 Mohammad Qasaymeh,2 Shadi Qasem,3 Emily De Los Reyes4 1Kids Neuro Clinic and Rehab Center, Dubai, United Arab Emirates; 2Pediatric Neurology, Dent Neurological Institute, Amherst, NY, USA; 3Pathology and Laboratory Medicine, University of Kentucky College of Medicine, Lexington, KY, USA; 4Pediatric Neurology, Nationwide Children’s Hospital and Ohio State University, Columbus, OH, USACorrespondence: Hamza A AlsayoufKids Neuro Clinic and Rehab Center, Dubai Healthcare City, Dubai, United Arab EmiratesTel +97 145570326Email leeamra1000@gmail.comPurpose: Autism spectrum disorder (ASD) is a debilitating neurodevelopmental disorder with high heterogeneity and no clear common cause. Several drugs, in particular risperidone and aripiprazole, are used to treat comorbid challenging behaviors in children with ASD. Treatment with risperidone and aripiprazole is currently recommended by the Food and Drug Administration (FDA) in the USA for children aged 5 and 6 years and older, respectively. Here, we investigated the use of these medications in younger patients aged 4 years and older.Patients and Methods: This retrospective case series included 18 children (mean age, 5.7 years) with ASD treated at the Kids Neuro Clinic and Rehab Center in Dubai. These patients began treatment with risperidone or aripiprazole at the age of 4 years and older, and all patients presented with comorbid challenging behaviors that warranted pharmacological intervention with either risperidone or aripiprazole.Results: All 18 children showed objective improvement in their ASD core signs and symptoms. Significant improvement was observed in 44% of the cases, and complete resolution (minimal-to-no-symptoms) was observed in 56% of the cases as per the Childhood Autism Rating Scale 2-Standard Test (CARS2-ST) and the Clinical Global Impression (CGI) scales.Conclusion: Our findings indicate that the chronic administration of antipsychotic medications with or without ADHD medications is well tolerated and efficacious in the treatment of ASD core and comorbid symptoms in younger children when combined with standard supportive therapies. This is the first report to suggest a treatment approach that may completely resolve the core signs and symptoms of ASD. While the reported outcomes indicate significant improvement to complete resolution of ASD, pharmacological intervention should continue to be considered as part of a multi-component intervention in combination with standard supportive therapies. Furthermore, the findings support the critical need for double-blind, placebo-controlled studies to validate the outcomes.Keywords: risperidone, aripiprazole, antipsychotic, comorbid challenging behaviorsAlsayouf HATalo HBiddappa MLQasaymeh MQasem SDe Los Reyes EDove Medical Pressarticlerisperidonearipiprazoleantipsychoticcomorbid challenging behaviors.Neurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 16, Pp 2779-2794 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	risperidone aripiprazole antipsychotic comorbid challenging behaviors. Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	risperidone aripiprazole antipsychotic comorbid challenging behaviors. Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Alsayouf HA Talo H Biddappa ML Qasaymeh M Qasem S De Los Reyes E Pharmacological Intervention in Children with Autism Spectrum Disorder with Standard Supportive Therapies Significantly Improves Core Signs and Symptoms: A Single-Center, Retrospective Case Series
description	Hamza A Alsayouf,1 Haitham Talo,1 Marisa L Biddappa,1 Mohammad Qasaymeh,2 Shadi Qasem,3 Emily De Los Reyes4 1Kids Neuro Clinic and Rehab Center, Dubai, United Arab Emirates; 2Pediatric Neurology, Dent Neurological Institute, Amherst, NY, USA; 3Pathology and Laboratory Medicine, University of Kentucky College of Medicine, Lexington, KY, USA; 4Pediatric Neurology, Nationwide Children’s Hospital and Ohio State University, Columbus, OH, USACorrespondence: Hamza A AlsayoufKids Neuro Clinic and Rehab Center, Dubai Healthcare City, Dubai, United Arab EmiratesTel +97 145570326Email leeamra1000@gmail.comPurpose: Autism spectrum disorder (ASD) is a debilitating neurodevelopmental disorder with high heterogeneity and no clear common cause. Several drugs, in particular risperidone and aripiprazole, are used to treat comorbid challenging behaviors in children with ASD. Treatment with risperidone and aripiprazole is currently recommended by the Food and Drug Administration (FDA) in the USA for children aged 5 and 6 years and older, respectively. Here, we investigated the use of these medications in younger patients aged 4 years and older.Patients and Methods: This retrospective case series included 18 children (mean age, 5.7 years) with ASD treated at the Kids Neuro Clinic and Rehab Center in Dubai. These patients began treatment with risperidone or aripiprazole at the age of 4 years and older, and all patients presented with comorbid challenging behaviors that warranted pharmacological intervention with either risperidone or aripiprazole.Results: All 18 children showed objective improvement in their ASD core signs and symptoms. Significant improvement was observed in 44% of the cases, and complete resolution (minimal-to-no-symptoms) was observed in 56% of the cases as per the Childhood Autism Rating Scale 2-Standard Test (CARS2-ST) and the Clinical Global Impression (CGI) scales.Conclusion: Our findings indicate that the chronic administration of antipsychotic medications with or without ADHD medications is well tolerated and efficacious in the treatment of ASD core and comorbid symptoms in younger children when combined with standard supportive therapies. This is the first report to suggest a treatment approach that may completely resolve the core signs and symptoms of ASD. While the reported outcomes indicate significant improvement to complete resolution of ASD, pharmacological intervention should continue to be considered as part of a multi-component intervention in combination with standard supportive therapies. Furthermore, the findings support the critical need for double-blind, placebo-controlled studies to validate the outcomes.Keywords: risperidone, aripiprazole, antipsychotic, comorbid challenging behaviors
format	article
author	Alsayouf HA Talo H Biddappa ML Qasaymeh M Qasem S De Los Reyes E
author_facet	Alsayouf HA Talo H Biddappa ML Qasaymeh M Qasem S De Los Reyes E
author_sort	Alsayouf HA
title	Pharmacological Intervention in Children with Autism Spectrum Disorder with Standard Supportive Therapies Significantly Improves Core Signs and Symptoms: A Single-Center, Retrospective Case Series
title_short	Pharmacological Intervention in Children with Autism Spectrum Disorder with Standard Supportive Therapies Significantly Improves Core Signs and Symptoms: A Single-Center, Retrospective Case Series
title_full	Pharmacological Intervention in Children with Autism Spectrum Disorder with Standard Supportive Therapies Significantly Improves Core Signs and Symptoms: A Single-Center, Retrospective Case Series
title_fullStr	Pharmacological Intervention in Children with Autism Spectrum Disorder with Standard Supportive Therapies Significantly Improves Core Signs and Symptoms: A Single-Center, Retrospective Case Series
title_full_unstemmed	Pharmacological Intervention in Children with Autism Spectrum Disorder with Standard Supportive Therapies Significantly Improves Core Signs and Symptoms: A Single-Center, Retrospective Case Series
title_sort	pharmacological intervention in children with autism spectrum disorder with standard supportive therapies significantly improves core signs and symptoms: a single-center, retrospective case series
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/b1791cdb32f448f2993bad759a6eb043
work_keys_str_mv	AT alsayoufha pharmacologicalinterventioninchildrenwithautismspectrumdisorderwithstandardsupportivetherapiessignificantlyimprovescoresignsandsymptomsasinglecenterretrospectivecaseseries AT taloh pharmacologicalinterventioninchildrenwithautismspectrumdisorderwithstandardsupportivetherapiessignificantlyimprovescoresignsandsymptomsasinglecenterretrospectivecaseseries AT biddappaml pharmacologicalinterventioninchildrenwithautismspectrumdisorderwithstandardsupportivetherapiessignificantlyimprovescoresignsandsymptomsasinglecenterretrospectivecaseseries AT qasaymehm pharmacologicalinterventioninchildrenwithautismspectrumdisorderwithstandardsupportivetherapiessignificantlyimprovescoresignsandsymptomsasinglecenterretrospectivecaseseries AT qasems pharmacologicalinterventioninchildrenwithautismspectrumdisorderwithstandardsupportivetherapiessignificantlyimprovescoresignsandsymptomsasinglecenterretrospectivecaseseries AT delosreyese pharmacologicalinterventioninchildrenwithautismspectrumdisorderwithstandardsupportivetherapiessignificantlyimprovescoresignsandsymptomsasinglecenterretrospectivecaseseries
_version_	1718396242399068160

Pharmacological Intervention in Children with Autism Spectrum Disorder with Standard Supportive Therapies Significantly Improves Core Signs and Symptoms: A Single-Center, Retrospective Case Series

Ejemplares similares